Skip to main content

Table 1 Baseline characteristics stratified by gender and treatment group. Baseline characteristics of patients in the per-protocol population. Numbers are N (%) unless otherwise stated

From: Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

Characteristics Control group (N = 510) Isoniazid group (N = 514) Ethambutol group (N = 524) All patients (N = 1548)
Sex Male (N = 356) Female (N = 154) Male (N = 351) Female (N = 163) Male (N = 369) Female (N = 155) Male (N = 1076) Female (N = 472)
Age group*
 ≤ 30 years 155 (44) 89 (58) 170 (48) 84 (52) 161 (44) 80 (52) 486 (45) 253 (54)
 > 30 years 201 (56) 65 (42) 181 (52) 79 (48) 208 (56) 75 (48) 590 (55) 219 (46)
Weight group*
 < 40 kg 14 (4) 36 (23) 14 (4) 30 (18) 29 (8) 29 (19) 57 (5) 95 (20)
 40–45 kg 45 (13) 35 (23) 54 (15) 36 (22) 54 (15) 28 (18) 153 (14) 99 (21)
 > 45–55 kg 163 (46) 43 (28) 159 (45) 51 (31) 149 (40) 55 (35) 471 (44) 149 (32)
 > 55 kg 134 (38) 40 (26) 124 (35) 46 (28) 137 (37) 43 (28) 395 (37) 129 (27)
BMI
 < 18.5 196 (55) 71 (46) 199 (57) 73 (45) 211 (57) 64 (41) 606 (56) 208 (44)
 ≥ 18.5 160 (45) 83 (54) 152 (43) 90 (55) 158 (43) 91 (59) 470 (44) 264 (56)
Race or ethnic group*
 Black 171 (48) 67 (44) 150 (43) 60 (37) 173 (47) 64 (41) 494 (46) 191 (40)
 Asian 109 (31) 51 (33) 107 (30) 47 (29) 119 (32) 42 (27) 335 (31) 140 (30)
 Mixed race or other 76 (21) 36 (23) 94 (27) 56 (34) 77 (21) 49 (32) 247 (23) 141 (30)
Smoking status*
 Never 133 (37) 113 (73) 121 (34) 110 (67) 127 (34) 103 (66) 381 (35) 326 (69)
 Past 105 (29) 14 (9) 100 (28) 11 (7) 117 (32) 17 (11) 322 (30) 42 (9)
 Current 118 (33) 27 (18) 130 (37) 42 (26) 125 (34) 35 (23) 373 (35) 104 (22)
HIV positivity* 21 (6) 17 (11) 23 (7) 14 (9) 17 (5) 18 (12) 61 (6) 49 (10)
Cavitation*ǁ 268 (75) 100 (65) 244 (70) 113 (69) 264 (72) 103 (66) 776 (72) 316 (67)
Area of lung involvement (%, (SD)) 21.5 (12.5) 20.1 (12.4) 20.9 (13.1) 19.2 (12.1) 20.9 (12.2) 19.7 (11.0) 21.1 (12.6) 19.7 (11.9)
Smear grading
 Neg 14 (4) 7 (5) 14 (4) 5 (3) 17 (5) 7 (5) 45 (4) 19 (4)
 1+ 32 (9) 15 (10) 24 (7) 17 (10) 25 (7) 14 (9) 81 (8) 46 (10)
 2+ 43 (12) 19 (12) 52 (15) 26 (16) 62 (17) 22 (14) 157 (15) 67 (14)
 3+ 86 (24) 42 (27) 79 (23) 37 (23) 82 (22) 32 (21) 247 (23) 111 (24)
 4+ 181 (51) 71 (46) 182 (52) 78 (48) 183 (50) 80 (52) 546 (51) 229 (49)
LJ
 Positive 283 (79) 117 (76) 277 (79) 137 (84) 294 (80) 132 (85) 854 (81) 386 (82)
 Negative 33 (9) 14 (9) 25 (7) 12 (7) 31 (8) 4 (3) 89 (8) 30 (6)
 Contaminated 29 (8) 16 (10) 38 (11) 14 (9) 33 (9) 16 (10) 100 (9) 46 (10)
 Indeterminate 11 (3) 7 (5) 11 (3) 0 (0) 11 (3) 3 (2) 33 (3) 10 (2)
 TTD (median [IQR]) 14 [14–21] 14 [14–21] 14 [14–25] 14 [14–21] 21 [14–28] 14 [14–21] 14 [14–21] 14 [14–21]
MGIT
 Positive 329 (92) 141 (92) 319 (93) 157 (96) 332 (90) 147 (95) 980 (93) 445 (94)
 Negative 5 (1) 2 (1) 4 (1) 0 (0) 7 (2) 2 (1) 16 (2) 4 (1)
 Contaminated 11 (3) 4 (3) 10 (3) 6 (4) 15 (4) 3 (2) 36 (3) 13 (3)
 False positive 2 (1) 0 (0) 5 (1) 0 (0) 4 (1) 0 (0) 11 (1) 0 (0)
 Indeterminate 9 (3) 7 (5) 13 (4) 0 (0) 11 (3) 3 (2) 13 (1) 10 (2)
 TTP (median [IQR]) 4.81 [3.71–6.66] 5.13 [3.79–6.79] 4.92 [3.70–6.39] 5.04 [4.03–6.43] 4.83 [3.67–6.58] 4.73 [3.70–6.50] 4.83 [3.71–6.50] 5.04 [3.88–6.46]
  1. p values for categorical variables are calculated using chi-squared test and for the continuous variable using Mann-Whitney U test
  2. HIV human immunodeficiency virus, TTD time to detect a positive culture in days on LJ media, TTP time to detect a positive culture in days in MGIT, IQR interquartile range
  3. *Males and females were significantly different at baseline for weight, age, race, smoking, HIV, cavitation, area of lung involvement and LJ TTD; p values were ≤ 0.001, 0.002, 0.013, ≤ 0.001, 0.001, 0.022, 0.05 and 0.04 respectively
  4. Race or ethnic group was reported by the investigator. Asian category included both South Asians and East Asians. Mixed race or other included mixed race, coloured and Caucasian
  5. ǁCavitation status was missing for 148 patients